Quest Diagnostics (DGX) return on equity (ROE)

Return on equity · fiscal 2025
13.8%

Quest Diagnostics (DGX) earned a return on equity of 13.8% in fiscal 2025 (the year ended December 31, 2025). That is 1.0 percentage points higher than the 12.9% of fiscal 2024. Figures as of 17 Nov 2026, 23:29 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
13.8%
Change on fiscal 2024
+1.0 pts
Highest on record
31.0%fiscal 2021
Lowest on record
10.2%fiscal 2007
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Quest Diagnostics return on equity (ROE), in more detail

Across the 19 fiscal years on record (2007–2025), the highest was 31.0% in fiscal 2021 and the lowest 10.2% in fiscal 2007. The fiscal 2025 figure is higher than in 33% of the 18 earlier fiscal years on record, whose median is 15.2%.

History · 19 fiscal years

Return on equity by fiscal year

Quest Diagnostics return on equity (ROE), year by year

Quest Diagnostics (DGX) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202513.8% 1.0 pts up
202412.9% 0.7 pts down
202313.5% 2.5 pts down
202216.1% 14.9 pts down
202131.0% 9.8 pts up
202021.2% 6.0 pts up
201915.2% 1.1 pts up
201814.1% 1.6 pts down
201715.7% 1.8 pts up
201613.9% 1.2 pts down
201515.1% 2.2 pts up
201412.9% 8.6 pts down
201321.5% 8.1 pts up
201213.4% 0.6 pts up
201112.8% 5.1 pts down
201017.9% 0.4 pts down
200918.3% 2.1 pts up
200816.1% 6.0 pts up
200710.2%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Quest Diagnostics and comparable companies
CompanyReturn on equityFiscal year
Labcorp Holdings LH10.2%2025
DexCom DXCM30.5%2025
Koninklijke Philips PHG8.2%2025
Roivant Sciences ROIV-6.6%2026
West Pharmaceutical Services WST15.5%2025
Quest Diagnostics DGX13.8%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on DGX

Quest Diagnostics, figure by figure

Quest Diagnostics (DGX) overview: price, valuation and scorecardAll health care companies by market value

Quest Diagnostics return on equity (ROE): questions and answers

What is Quest Diagnostics's return on equity?

Quest Diagnostics (DGX) earned a return on equity of 13.8% in fiscal 2025 (the year ended December 31, 2025). That is 1.0 percentage points higher than the 12.9% of fiscal 2024.

Is Quest Diagnostics's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 33% of the 18 earlier fiscal years on record, whose median is 15.2%.

What are the highest and lowest return on equity figures on record for Quest Diagnostics?

Across the 19 fiscal years on record (2007–2025), the highest was 31.0% in fiscal 2021 and the lowest 10.2% in fiscal 2007.

How is Quest Diagnostics's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Quest Diagnostics (DGX) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/DGX/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.